Rituximab in ANCA-associated vasculitis: a revolution?

On 19 April 2011, the US Food and Drug Administration (FDA) approved rituximab in combination with glucocorticosteroids for the treatment of two forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV): granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rituximab is the first FDA approved drug for ANCA-associated vasculitis.

Rest of this article is here.

What I have to say: From talking to patients who are taking this treatment, they have less side-effects than using cyclophosphamide. This is a great break-through for Vasculitis patients.


About Cyn Bagley

My life is a mixture of travel, jobs, and disease. You can find some of my novels on amazon.com under the name Cyn Bagley.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s